Hologic (NASDAQ:HOLX) Receives New Coverage from Analysts at Citigroup

Equities research analysts at Citigroup initiated coverage on shares of Hologic (NASDAQ:HOLX) in a report released on Monday, January 6th, Marketbeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the medical equipment provider’s stock. Citigroup‘s price target points to a potential upside of 11.26% from the stock’s current price.

Several other brokerages have also recently issued reports on HOLX. Morgan Stanley cut Hologic from an “equal weight” rating to an “underweight” rating in a research report on Thursday, January 2nd. Stifel Nicolaus lifted their price objective on shares of Hologic from $48.00 to $52.00 and gave the company a “hold” rating in a research report on Friday, December 13th. TheStreet downgraded shares of Hologic from a “b-” rating to a “c” rating in a report on Wednesday, November 6th. William Blair restated a “buy” rating on shares of Hologic in a research report on Thursday, November 21st. Finally, ValuEngine upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. Hologic currently has a consensus rating of “Hold” and a consensus price target of $55.38.

HOLX traded up $0.18 during midday trading on Monday, hitting $53.93. The stock had a trading volume of 40,961 shares, compared to its average volume of 1,605,262. The company has a market cap of $14.35 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 2.35 and a beta of 0.76. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.68. Hologic has a 1 year low of $42.61 and a 1 year high of $54.24. The business has a fifty day moving average of $52.43 and a 200 day moving average of $49.79.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 EPS for the quarter, hitting analysts’ consensus estimates of $0.65. The company had revenue of $865.80 million for the quarter, compared to analysts’ expectations of $846.54 million. Hologic had a negative net margin of 1.19% and a positive return on equity of 29.67%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.58 EPS. On average, equities research analysts anticipate that Hologic will post 2.62 earnings per share for the current year.

In related news, CEO Stephen P. Macmillan sold 194,396 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $45.91, for a total transaction of $8,924,720.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel John M. Griffin sold 19,624 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $52.86, for a total value of $1,037,324.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 251,453 shares of company stock valued at $11,871,295. Insiders own 0.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of HOLX. Nuveen Asset Management LLC raised its holdings in Hologic by 72,308.7% during the second quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock worth $254,730,000 after acquiring an additional 5,297,332 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Hologic by 203.5% in the second quarter. Point72 Asset Management L.P. now owns 1,056,488 shares of the medical equipment provider’s stock worth $50,733,000 after buying an additional 708,361 shares during the period. AQR Capital Management LLC grew its holdings in shares of Hologic by 323.0% during the second quarter. AQR Capital Management LLC now owns 415,932 shares of the medical equipment provider’s stock valued at $19,973,000 after buying an additional 317,614 shares in the last quarter. Parnassus Investments CA raised its position in Hologic by 1.9% during the third quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock valued at $799,048,000 after buying an additional 300,090 shares during the period. Finally, Man Group plc lifted its stake in Hologic by 30.2% in the 3rd quarter. Man Group plc now owns 1,292,169 shares of the medical equipment provider’s stock worth $65,241,000 after acquiring an additional 299,581 shares in the last quarter. 94.06% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Technical Indicators – What is a Golden Cross?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.